Sexually Transmitted Diseases, BacterialNCT04182230
UROGEN WELL D-ONE : Evaluation of a Novel Diagnostic for Sexually Transmitted Bacterial Infections
An observational study of Sexually Transmitted Diseases, Bacterial and Bacterial Urinary Tract Infection, run by Cwm Taf University Health Board (NHS) at 1 site in United Kingdom.
Trial summary
UROGEN WELL D-ONE Principal research question: Can the UROGEN WELL D-ONE assay detect urinary tract infections and urethritis in clinical samples from patients attending Genitourinary Medicine outpatient clinics as accurately as standard laboratory microscopy and culture methodologies, while simultaneously identifying… Read more about this study
- Who is it for?
- Ages 16 to 100 years
- Conditions the study is for
- Sexually Transmitted Diseases, Bacterial, Bacterial Urinary Tract Infection, Antimicrobial Resistance
- How many people
- 500 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 5 Sep 2018to 5 Sep 2019
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 to 100 years
- All sexes
- Child, Adult, Older adult
Study population: Participants who sexually active and attending a walk-in sexual health clinic for sexually transmitted infection testing and contraception provision.
Who may be able to join
- Participants must be sexually active. Participants will only be able to consent to this study if they have read and understood the Participant Information Sheet and been consented by a research nurse.
Who cannot join
- Patients aged under 16 years. Patients who are victims of sexual assault Patients who are not sexually active Patients who are deemed unable to give informed consent.
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
Department of Sexual Health, Cwm Taf University Health board
Llantrisant, CF37 1LB
About this study
Official title: UROGEN WEL-DONE: Can the Novel Rapid Diagnostic UROGEN WELL D-ONE Detect Common Causes of Urinary Tract Infections and Urethritis?
UROGEN WELL D-ONE
Principal research question:
Read more
Can the UROGEN WELL D-ONE assay detect urinary tract infections and urethritis in clinical samples from patients attending Genitourinary Medicine outpatient clinics as accurately as standard laboratory microscopy and culture methodologies, while simultaneously identifying antimicrobial resistance?
The primary aim of this study is to evaluate the rapid diagnostic assay UROGEN WELL D-ONE and determine if it can accurately detect infectious organisms causing UTI's and urethritis.
Secondary research question:
Is the antimicrobial resistance identified by the UROGEN WELL D-ONE assay accurate as compared to determination by the Clinical and Laboratory Standards Institute international guidelines?
The secondary research objective will be to assess the accuracy of the breakpoint antimicrobial susceptibility measurement by the assay. This is particularly important with the global increase in antibiotic resistance, when the acquisition of mobile resistance genes to the remaining effective therapeutics is rising internationally.
Read the detailed description
UROGEN WELL D-ONE is a new rapid culture-based benchtop diagnostic for the detection of urinary tract infections and urethritis. It detects the causative organisms and determines their antibiotic resistance. The novel test can detect bacterial infections such as E. coli, Staphylococcus spp., Enterococcus, Group B Streptococci, Mycoplasma spp, Ureaplasma spp, Neisseria spp, Gardnerella vaginalis, the protozoa Trichomonas vaginalis and Candida albicans. As such this diagnostic could be a very good tool to detect infection, identify the organism responsible for infection and with determination of antimicrobial susceptibility, guide treatment of these infections.
BACKGROUND- Urinary tract infections (UTIs) are a severe public health problem and are caused by a range of pathogens. High recurrence rates and increasing antimicrobial resistance among uropathogens threaten to greatly increase the economic burden of these infections. Urinary tract infections (UTIs) are some of the most common bacterial infections, affecting 150 million people each year worldwide1 UTIs are caused by both Gram-negative and Gram-positive bacteria, as well as by certain fungi. The most common causative agent for both uncomplicated and complicated UTIs is uropathogenic Escherichia coli (UPEC). For the agents involved in uncomplicated UTIs, UPEC is followed in prevalence by Staphylococcus saprophyticus, Enterococcus faecalis, group B Streptococcus (GBS), Neisseria spp., Staphylococcus aureus and Candida spp.2-5 Multidrug-resistant uropathogenic organisms are becoming an expanding public health threat, as Enterobacteriaceae family members increasingly acquire extended-spectrum β-lactamases, such as cefotaximases, oxacillinases, AmpC-type β-lactamases and carbapenemases.8-9. Routine testing techniques currently used for antibiotic sensitivity of pathogens causing UTIs can take 2-3 days to perform and so accurate treatment is often delayed. This delays treatment and can lead to increased morbidity.
Urethritis or inflammation of the urethra, is a multifactorial condition which is sexually acquired in the majority of (but not all) cases. It is characterised by urethral discharge, dysuria and/or urethral discomfort. Urethritis is described as either gonococcal, when Neisseria gonorrhoeae is detected, or nongonococcal (NGU) when it is not. Organisms implicated in this disease are commonly Chlamydia trachomatis, Mycoplasma spp, Ureaplasma spp, Trichomonas vaginalis and Candida. A number of studies indicate that antibiotic resistance in some of these organisms leads to microbiological failure of treatment, up to 68% for tetracyclines.11,13,14 , up to 33% for macrolides 10,11,13-18 and that mutations in the quinolone-resistance determining regions (QRDRs) of the gyrA and parC genes can occur with a prevalence of 10%19. Persistent NGU, when symptoms do not resolve following treatment, occurs in 15%-25% of patients following initial treatment of acute NGU. Recurrent NGU is empirically defined as the recurrence occurs in 10%-20% of patients.12,20 The aetiology of persistent NGU is probably multifactorial with a persistent infectious agent being identified in 50% of cases.11,12,20,21 Currently, testing for the detection of UTI and urethritis is expensive, requires highly trained laboratory staff and takes 48-72 hours. This delays treatment and can lead to increased morbidity. However, UROGEN WELL D-ONE is a new rapid culture-based clinical diagnostic assay, which will improve clinical provision for the detection of the cause of urinary tract infections and urethritis from urine samples e.g E. coli, Gardnerella vaginalis, Group B Streptococcus, Staphylococcus aureus, Neisseria spp., Enterococcus, E. Coli, Mycoplasma and Ureaplasma spp, the protozoa Trichomonas vaginalis and Candida albicans. It will also demonstrate their antimicrobial susceptibility. Importantly it uses the correct CLSI antibiotic threshold concentrations to determine antimicrobial resistance and does not require specialist equipment.
In summary, UROGEN WELL D-ONE has the potential to allow rapid detection of the common organisms that cause UTI and urethritis and guide antibiotic treatment, with a turnaround time of 18 hours. This has highly significant positive outcomes for patients and reduce empirical treatment of infection.
- Conditions
- Sexually Transmitted Diseases, Bacterial, Bacterial Urinary Tract Infection, Antimicrobial Resistance
- Being tested
- No intervention. This study was an evalution with no intervention.
- Keywords
- Sexually transmitted infections
- Medical subject headings
- Sexually Transmitted Diseases, Bacterial, Sexually Transmitted Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No intervention. This study was an evalution with no intervention.Other
Not an interventional study
What is being measured
The primary outcome is the main question the study is designed to answer.
UROGEN WELL D-ONE PRIMARY OUTCOME
The primary aim of this study is to evaluate the rapid diagnostic assay UROGEN WELL D-ONE and determine the sensitivity and specificity of the assay for the detection of sexually transmitted bacterial infections.
Measured: 365 days
Secondary outcomes (1)
UROGEN WELL D-ONE SECONDARY OUTCOME
To determine the specificity and sensitivity of the assay for detection of antimicrobial resistance of bacteria and compare to determination by the Clinical and Laboratory Standards Institute international guidelines.
Measured: 365 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Dec 2019
- Study start5 Sep 2018
- Primary completion5 Sep 2019
- Study completion5 Sep 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Sexually Transmitted Diseases, BacterialStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 500 participants (actual)
Sponsor and investigators
- Lead sponsor
- Cwm Taf University Health Board (NHS)
- Sponsor type
- Other government
- Collaborators
- Cardiff University
- Responsible party
- Sponsor
- Investigators
- Lucy C Jones, DM, Principal investigator, Cwm Taf University Health Board (NHS)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04182230
- Sponsor's protocol ID
- CT 251053 3/07/18
- Status last verified
- Nov 2019
- First submitted
- 27 Nov 2019
- Last updated
- 2 Dec 2019
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Dec 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- UROGEN WEL-DONE: Can the Novel Rapid Diagnostic UROGEN WELL D-ONE Detect Common Causes of Urinary Tract Infections and Urethritis?
- ClinicalTrials.gov ID
- NCT04182230
- Acronym / sponsor ID
- CT 251053 3/07/18
- Conditions
- Sexually Transmitted Diseases, Bacterial, Bacterial Urinary Tract Infection, Antimicrobial Resistance
- Keywords
- Sexually transmitted infections
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 500 participants (actual)
- Lead sponsor
- Cwm Taf University Health Board (NHS)Other government
- Collaborators
- Cardiff University
- Study start
- 5 Sep 2018 (actual)
- Primary completion
- 5 Sep 2019 (actual)
- Study completion
- 5 Sep 2019 (actual)
- First posted
- 2 Dec 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
UROGEN WELL D-ONE
Principal research question:
Can the UROGEN WELL D-ONE assay detect urinary tract infections and urethritis in clinical samples from patients attending Genitourinary Medicine outpatient clinics as accurately as standard laboratory microscopy and culture methodologies, while simultaneously identifying antimicrobial resistance?
The primary aim of this study is to evaluate the rapid diagnostic assay UROGEN WELL D-ONE and determine if it can accurately detect infectious organisms causing UTI's and urethritis.
Secondary research question:
Is the antimicrobial resistance identified by the UROGEN WELL D-ONE assay accurate as compared to determination by the Clinical and Laboratory Standards Institute international guidelines?
The secondary research objective will be to assess the accuracy of the breakpoint antimicrobial susceptibility measurement by the assay. This is particularly important with the global increase in antibiotic resistance, when the acquisition of mobile resistance genes to the remaining effective therapeutics is rising internationally.
Detailed description
UROGEN WELL D-ONE is a new rapid culture-based benchtop diagnostic for the detection of urinary tract infections and urethritis. It detects the causative organisms and determines their antibiotic resistance. The novel test can detect bacterial infections such as E. coli, Staphylococcus spp., Enterococcus, Group B Streptococci, Mycoplasma spp, Ureaplasma spp, Neisseria spp, Gardnerella vaginalis, the protozoa Trichomonas vaginalis and Candida albicans. As such this diagnostic could be a very good tool to detect infection, identify the organism responsible for infection and with determination of antimicrobial susceptibility, guide treatment of these infections.
BACKGROUND- Urinary tract infections (UTIs) are a severe public health problem and are caused by a range of pathogens. High recurrence rates and increasing antimicrobial resistance among uropathogens threaten to greatly increase the economic burden of these infections. Urinary tract infections (UTIs) are some of the most common bacterial infections, affecting 150 million people each year worldwide1 UTIs are caused by both Gram-negative and Gram-positive bacteria, as well as by certain fungi. The most common causative agent for both uncomplicated and complicated UTIs is uropathogenic Escherichia coli (UPEC). For the agents involved in uncomplicated UTIs, UPEC is followed in prevalence by Staphylococcus saprophyticus, Enterococcus faecalis, group B Streptococcus (GBS), Neisseria spp., Staphylococcus aureus and Candida spp.2-5 Multidrug-resistant uropathogenic organisms are becoming an expanding public health threat, as Enterobacteriaceae family members increasingly acquire extended-spectrum β-lactamases, such as cefotaximases, oxacillinases, AmpC-type β-lactamases and carbapenemases.8-9. Routine testing techniques currently used for antibiotic sensitivity of pathogens causing UTIs can take 2-3 days to perform and so accurate treatment is often delayed. This delays treatment and can lead to increased morbidity.
Urethritis or inflammation of the urethra, is a multifactorial condition which is sexually acquired in the majority of (but not all) cases. It is characterised by urethral discharge, dysuria and/or urethral discomfort. Urethritis is described as either gonococcal, when Neisseria gonorrhoeae is detected, or nongonococcal (NGU) when it is not. Organisms implicated in this disease are commonly Chlamydia trachomatis, Mycoplasma spp, Ureaplasma spp, Trichomonas vaginalis and Candida. A number of studies indicate that antibiotic resistance in some of these organisms leads to microbiological failure of treatment, up to 68% for tetracyclines.11,13,14 , up to 33% for macrolides 10,11,13-18 and that mutations in the quinolone-resistance determining regions (QRDRs) of the gyrA and parC genes can occur with a prevalence of 10%19. Persistent NGU, when symptoms do not resolve following treatment, occurs in 15%-25% of patients following initial treatment of acute NGU. Recurrent NGU is empirically defined as the recurrence occurs in 10%-20% of patients.12,20 The aetiology of persistent NGU is probably multifactorial with a persistent infectious agent being identified in 50% of cases.11,12,20,21 Currently, testing for the detection of UTI and urethritis is expensive, requires highly trained laboratory staff and takes 48-72 hours. This delays treatment and can lead to increased morbidity. However, UROGEN WELL D-ONE is a new rapid culture-based clinical diagnostic assay, which will improve clinical provision for the detection of the cause of urinary tract infections and urethritis from urine samples e.g E. coli, Gardnerella vaginalis, Group B Streptococcus, Staphylococcus aureus, Neisseria spp., Enterococcus, E. Coli, Mycoplasma and Ureaplasma spp, the protozoa Trichomonas vaginalis and Candida albicans. It will also demonstrate their antimicrobial susceptibility. Importantly it uses the correct CLSI antibiotic threshold concentrations to determine antimicrobial resistance and does not require specialist equipment.
In summary, UROGEN WELL D-ONE has the potential to allow rapid detection of the common organisms that cause UTI and urethritis and guide antibiotic treatment, with a turnaround time of 18 hours. This has highly significant positive outcomes for patients and reduce empirical treatment of infection.
Study design
- Observational model
- Other
- Time perspective
- Prospective
Who may qualify
- Ages
- 16 to 100 years
- Sex
- All
- Age groups
- Child, Adult, Older adult
- Study population
- Participants who sexually active and attending a walk-in sexual health clinic for sexually transmitted infection testing and contraception provision.
Key inclusion criteria (1 listed)
- Participants must be sexually active. Participants will only be able to consent to this study if they have read and understood the Participant Information Sheet and been consented by a research nurse.
Key exclusion criteria (1 listed)
- Patients aged under 16 years. Patients who are victims of sexual assault Patients who are not sexually active Patients who are deemed unable to give informed consent.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No intervention. This study was an evalution with no intervention.Not an interventional study | Other | – |
Primary outcome
UROGEN WELL D-ONE PRIMARY OUTCOME
Time frame: 365 days
The primary aim of this study is to evaluate the rapid diagnostic assay UROGEN WELL D-ONE and determine the sensitivity and specificity of the assay for the detection of sexually transmitted bacterial infections.
1 secondary outcome
UROGEN WELL D-ONE SECONDARY OUTCOME
Time frame: 365 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Dec 2019.
- Individual participant dataSharing planned: No
Related trials for Sexually Transmitted Diseases, Bacterial
RecruitingPhase 1
Phase 1 Study of Chlamydia Trachomatis mRNA Vaccine in Adults.
Chlamydia Trachomatis Immunization
Active, not recruitingPhase 4
Periodic Presumptive Treatment vs. doxyPEP for STI Control in Kenyan MSM
Gonorrhea Male, Chlamydia (Male)
Not yet recruiting
Pilot HIV Self-Testing And Self-collected STI Testing Strategy for Sex Worker Empowerment Study
HIV, Syphilis
Recruiting
Bring BPaL2Me Trial Comparing Nurse-Led RR-TB Treatment to Physician-Led RR-TB Treatment
Drug Resistant Tuberculosis
Not yet recruitingPhase 3
A Clinical Study to Assess the Efficacy of Weekly Doxycycline Prophylaxis to Reduce Bacterial Sexually Transmitted Infections (STI) in Young African Women
Sexually Transmitted Infection (STI), Gonorrhea
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lucy C Jones, DM principal investigator
Cwm Taf University Health Board (NHS)
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Sexually Transmitted Diseases, Bacterial and Bacterial Urinary Tract Infection, run by Cwm Taf University Health Board (NHS) at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Dec 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
UROGEN WELL D-ONE PRIMARY OUTCOME (time frame: 365 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Dec 2019.